ClinicalTrials.gg
CompletedNCT04006457ALLEGRO-LTUpdated Apr 9, 2026Results posted

Long-Term PF-06651600 for the Treatment of Alopecia Areata

A Phase 3 interventional study of PF-06651600 and Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine in Alopecia Areata, sponsored by Pfizer. Completed at 144 sites in 17 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,057
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.

Enrollment
Largest of 10
1,057 · median 175
Started
2019
the only one that year
Phase 3
5 of 17
3 open now
Registered
3rd of 17
by date

Among the 17 studies in Alopecia Areata by Pfizer, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 3, and was the 3rd registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alopecia Areata by Pfizer, or all of them as a file.
02

Study summary

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug.

A sub-study of approximately 60 adult patients who are participating in the B7981032 study will be conducted at select sites in the US, Australia and Canada. The sub-study will evaluate the immune response to tetanus and meningococcal vaccines in patients who have received a minimum of 6 months of 50 mg PF-06651600.

03

Conditions studied

  • Alopecia Areata

Keywords

  • Alopecia
  • Alopecia Areata
  • Alopecia totalis
  • Alopecia universalis
  • Hair loss
  • JAK inhibitor
  • PF-06651600
  • Ritlecitinib
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria-

For de novo participants and participants from Study B7931005 and B7981015 with >30 days between first visit in B7981032 and last dose in the prior study:

  • Clinical diagnosis of alopecia areata (AA) with no other cause of hair loss. Androgenetic alopecia coexistent with AA is allowed.
  • De novo participants >=12 to \<18 years of age: >=50% terminal hair loss of the scalp due to AA, including alopecia totalis and alopecia universalis
  • De novo participants >=18 years of age and participants from Study B7931005 or B7981015 with >30 days between first visit in B7981032 and last dose in the prior study: >=25% terminal hair loss of the scalp due to AA, including alopecia totalis and alopecia universalis
  • No evidence of terminal scalp hair regrowth within 6 months (de novo only)
  • Current episode of terminal scalp hair loss \<=10 years (de novo only)

Exclusion Criteria-

For de novo participants and participants from Study B7931005 and B7981015 with >30 days between first visit in B7981032 and last dose in the prior study:

  • Hearing loss with progression over previous 5 years, or sudden hearing loss, or middle or inner ear disease, or other auditory condition that is considered acute, fluctuating or progressive
  • History of or current with the exception of adequately treated or excised non basal cell or squamous cell cancer of the skin or cervical carcinoma in situ
  • History of a single episode of disseminated herpes zoster or disseminated herpes simplex, or a history of more than one episode of localized, dermatomal herpes zoster
  • Infection requiring hospitalization, or parenteral antimicrobial therapy within 6 months prior to Day 1

Exclusion criteria for all participants:

- Participants who have previously taken Janus kinase (JAK) inhibitors other than PF-06651600 must have received the last dose >12 weeks prior to the screening visit

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,057 participants (actual)

Study arms

  • Experimental
    Treatment sequence 1

    Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 tablet or capsule given QD for 59 months. Patients participating in the vaccine sub-study will receive the 2 vaccines or one of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 56 visit of the main B7981032 study.

    Drug: PF-06651600 · Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine · Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine

  • Experimental
    Treatment sequence 2

    Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 tablet or capsule given QD for 59 months. Patients participating in the vaccine sub-study will receive the 2 vaccines or 1 of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 56 visit of the main B7981032 study.

    Drug: PF-06651600 · Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine · Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine

Interventions

  • 50 mg oral tablets/capsules

  • BiologicalTetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine

    Single intramuscular injection administered to patients participating in the vaccine sub-study

  • BiologicalMeningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine

    Single intramuscular injection administered to patients participating in the vaccine sub-study

06

What researchers measure

Primary outcomes

  1. Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent if the event had start date on or after the first dosing date of this study.

    Time frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)

  2. Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up Visit

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.

    Time frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)

  3. Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit

    Vital signs including blood pressure included systolic blood pressure (SBP) \[Millimeters of mercury, mmHg\]) and diastolic blood pressure (DBP) and pulse rate \[beats per minute (bpm)\] were measured using an automated device in a sitting position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Criteria for vital sign abnormalities included: SBP\<90mmHg, DBP\<50 mmHg and pulse rate\<40mmHg.

    Time frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)

  4. Main Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up Visit

    Criteria for laboratory abnormalities included:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \> 1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.

    Time frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)

  5. Vaccine Sub-study: Percentage of Participants With Tetanus Booster Response

    Booster response to tetanus toxoid was defined as: \>=4-fold rise in anti-tetanus toxoid immunoglobulin G (IgG) antibody concentration at Month 1 if the pre-vaccination concentration was \<=2.7 International Units per milliliter (IU/mL); OR \>=2-fold rise in anti-tetanus toxoid IgG antibody concentration if the pre-vaccination concentration was \>2.7 IU/mL. Two-sided 95% confidence interval (CI) was based on Clopper-Pearson exact method.

    Time frame: Month 1

Secondary outcomes

  1. Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until End of Study

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent if the event had start date on or after the first dosing date of this study.

    Time frame: From start of study intervention (Day 1) until end of study

  2. Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until End of Study

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.

    Time frame: From start of study intervention (Day 1) until end of study

  3. Main Study: Number of Participants With Clinically Significant Abnormalities in Vital Signs Until End of Study

    Vital signs including blood pressure (systolic and diastolic blood pressure \[Millimeters of mercury, mmHg\]) and pulse rate (beats per minute \[bpm\]) were measured using an automated device in a sitting position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Clinically significant abnormalities will be determined by investigator.

    Time frame: From start of study intervention (Day 1) until end of study

  4. Main Study: Number of Participants With Clinically Significant Laboratory Abnormalities Until End of Study

    Following laboratory parameters were assessed: Hemoglobin, Hematocrit, Erythrocytes Erythrocyte (ery.) corpuscular volume, Ery. Mean Corpuscular hemoglobin concentration, Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils, Monocytes, Prothrombin Time, Bilirubin, Direct Bilirubin, Indirect Bilirubin, Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase; Albumin, Urate; Urea Nitrogen, Creatinine, Cholesterol, Triglycerides, Potassium, Calcium, Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite, Leukocyte Erythrocytes, Leukocytes; Epithelial Cells, Hyaline Cast, Bacteria. Clinically significant abnormalities will be determined by investigator.

    Time frame: From start of study intervention (Day 1) until end of study

  5. Main Study: Percentage of Participants Achieving Response Based on Severity of Alopecia Tool (SALT) Overall Score <=10 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

    SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). In this outcome measure, percentage of participants with SALT overall score \<= 10 were reported. 95% CI was calculated based on normal approximation.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

  6. Main Study: Percentage of Participants Achieving Response Based on Alopecia Areata (AA) SALT Score <=10 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

    SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), with lower score indicating less hair loss. 95% CI was calculated based on normal approximation.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

  7. Main Study: Percentage of Participants Achieving Response Based on SALT Overall Score <= 20 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

    SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). In this outcome measure, percentage of participants with SALT overall score \<=20 were reported. 95% CI was calculated based on normal approximation.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

  8. Main Study: Percentage of Participants Achieving Response Based on AA SALT Score <=20 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

    SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), with lower score indicating less hair loss. 95% CI was calculated based on normal approximation.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

  9. Main Study: Change From Baseline in SALT Overall Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

    SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing division of scalp hair into four quadrants (back, top of scalp, right side and left side), with each of four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score is sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.

    Time frame: Baseline, At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

  10. Main Study: Change From Baseline in AA SALT Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

    SALT=quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into 4 quadrants (back, top of scalp, right side and left side), with each given an accurate determination of percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss). SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), lower score= less hair loss. Baseline (Roll-over participants: Day 1 from Study B7931005 or B7981015; De novo participants: Day 1 from Study B7981032).

    Time frame: Baseline, At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

  11. Main Study: Percentage of Participants Achieving Atleast 75% Improvement in Overall SALT Score From Baseline at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

    SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). An Overall SALT 75 response was a 75% or greater reduction from baseline in SALT score.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

  12. Main Study: Percentage of Participants Achieving Atleast 75% Improvement in AA SALT Score From Baseline at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

    SALT=quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score= SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), where lower score=less hair loss. SALT 75 response= 75% or greater reduction from baseline in AA SALT score.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

  13. Main Study: Percentage of Participants Achieving Atleast 2-Grade Improvement From Baseline or Absolute Score of 3 in the Eyebrow Assessment (EBA) at Months 1, 3, 6, 12, 18, 24 and 36 in Participants Without Normal EBA Score at Baseline

    EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow. Higher scores represent lesser loss of eyebrow hair. 95% CI was based on normal approximation.

    Time frame: At Months 1, 3, 6, 12, 18, 24 and 36

  14. Main Study: Percentage of Participants Achieving Atleast 2-Grade Improvement From Baseline or Absolute Score of 3 in the Eyelash Assessment (ELA) at Months 1, 3, 6, 12, 18, 24 and 36 in Participants Without Normal ELA Score at Baseline

    ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash. Higher scores represent lesser loss of eyelash hair.

    Time frame: At Months 1, 3, 6, 12, 18, 24 and 36

  15. Main Study: Percentage of Participants Achieving Patient's Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Months 1, 3, 6, 9, 12, 18, 24 and 36

    PGI-C is a self-administered single item questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. Participants were required to select their response on a 7-point scale ranging from 1 (greatly worsened), 2=moderately worsened, 3=slightly worsened, 4=not changed, 5= slightly improved, 6=moderately improved, 7 (greatly improved). 95% CI was based on normal approximation.

    Time frame: At Months 1, 3, 6, 9, 12, 18, 24 and 36

  16. Main Study: Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Months 1, 3, 6, 9, 12, 18, 24 and 36: Emotional Symptoms and Activity Limitations

    AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 5-8 assessed emotional symptoms with responses scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations with responses scored from 0='not at all' to 4='completely'. AAPPO emotional symptoms sub score was calculated as mean of items 5-8 and ranged from 0 (never) to 4 (always), where higher scores indicated more emotional symptoms. AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.

    Time frame: Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36

  17. Main Study: Percentage of Participants With Response Based on Hair Loss Improvement From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Months 1, 3, 6, 9, 12, 18, 24 and 36, Among Participants With Score >=2 at Baseline

    AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss from the scalp, eyebrows, eyelashes and body using a 5 point scale that ranged from 0 ='no hair loss' and 4='complete hair loss'. In this outcome measure, percentage of participants with AAPPO domain scores of 0 = no hair loss or 1 = a little hair loss, among participants with score \>=2 at baseline are reported.

    Time frame: Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36

  18. Main Study: Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Months 1, 3, 6, 9, 12, 18, 24 and 36

    HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The depression subscale comprised of 7 items with score ranging from 0 (no presence of depression) to 3 (severe feeling of depression). Total depression subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of depression symptoms. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.

    Time frame: Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36

  19. Main Study: Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Months 1, 3, 6, 9, 12, 18, 24 and 36

    HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The anxiety subscale comprised of 7 items with score ranging from 0 (no anxiety) to 3 (severe anxiety). Total anxiety subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of anxiety symptoms. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.

    Time frame: Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36

  20. Main Study: Percentage of Participants With Improvement on HADS Depression Score at Months 1, 3, 6, 9, 12, 18, 24 and 36

    HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The depression subscale comprised of 7 items with score ranging from 0 (no presence of depression) to 3 (severe feeling of depression). Total depression subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of depression symptoms. Improvement on HADS depression score was considered as achieving a "normal" depression subscale score indicative of an absence of depression. Among adults, a HADS-D score of 0-7 was considered "normal"; for adolescents, a HADS-D score of 0-6 was considered "normal". 95% CI was calculated based on normal approximation.

    Time frame: At Months 1, 3, 6, 9, 12, 18, 24 and 36

  21. Main Study: Percentage of Participants With Improvement on HADS Anxiety Score At Months 1, 3, 6, 9, 12, 18, 24 and 36

    HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The anxiety subscale comprised of 7 items with score ranging from 0 (no anxiety) to 3 (severe anxiety). Total anxiety subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of anxiety symptoms. Improvement on HADS anxiety score was considered as achieving a "normal" anxiety subscale score indicative of an absence of anxiety. Among adults, a HADS-A score of 0-7 was considered "normal"; for adolescents, a HADS-A score of 0-8 was considered "normal". 95% CI was calculated based on normal approximation.

    Time frame: At Months 1, 3, 6, 9, 12, 18, 24 and 36

  22. Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=1.0 International Units Per Milliliter (IU/mL) at Month 1-Tdap Vaccination

    Percentage of participants with anti-tetanus antibody level \>=1.0 IU/mL at Month 1 were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.

    Time frame: Month 1

  23. Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=0.1 IU/mL at Month 1-Tdap Vaccination

    Percentage of participants with anti-tetanus antibody level \>=0.1 IU/mL at Month 1 were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.

    Time frame: Month 1

  24. Vaccine Sub-study: Percentage of Participants With >=4 Times Increase in Anti-tetanus Antibody Level From Baseline at Month 1-Tdap Vaccination

    Percentage of participants with \>=4 times increase in anti-tetanus antibody level from baseline were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.

    Time frame: Month 1

  25. Vaccine Sub-study: Geometric Mean Fold Change in Anti-tetanus Levels Above Baseline Values at Month 1-Tdap Vaccination

    Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Fold change was defined as the ratio of the post-baseline result to the baseline result. The assay results below the LLOQ were set to 0.5 \* LLOQ except when pre-vaccination assay results is \< LLOQ while postvaccination result is \>= LLOQ, in which case the pre-vaccination value will be set to LLOQ.

    Time frame: From Baseline (pre-vaccination on Day 1) to Month 1

  26. Vaccine Sub-study: Geometric Mean Concentrations (GMCs) of Anti-tetanus Antibody Levels at Month 1-Tdap Vaccination

    Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Assay results below the LLOQ were set to 0.5\* LLOQ.

    Time frame: Month 1

  27. Vaccine Sub-study: Percentage of Participants With Human Serum Bactericidal Activity (hSBA) Titer >=1:8 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination

    Percentage of participants with hSBA titer \>=1.8 at 1 month post vaccination for serogroup C were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.

    Time frame: Month 1

  28. Vaccine Sub-study: Percentage of Participants With hSBA Titer >=1:4 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination

    Percentage of participants with hSBA titer \>=1.4 at 1 month post vaccination for serogroup C were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.

    Time frame: Month 1

  29. Vaccine Sub-study: Geometric Mean Titers (GMT) of Antibodies for Serogroup C at Baseline and Month 1-Meningococcal ACWY Vaccination

    Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Assay results below the LLOQ were set to 0.5\* LLOQ.

    Time frame: Baseline (pre-vaccination on Day 1) and Month 1

  30. Vaccine Sub-study: Number of Participants With SAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events.

    Time frame: From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)

  31. Vaccine Sub-study: Number of Participants With AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)

  32. Vaccine Sub-study: Number of Participants With AEs Leading to Discontinuation

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.

    Time frame: From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)

07

Results

Posted Aug 14, 2025

Participant flow

Main Study: Treatment Period 1
Participant flow — Main Study: Treatment Period 1
MilestoneMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine
Started4496030
Treated4476030
Completed2893320
Not completed1602710
Withdrew: Adverse event26360
Withdrew: Death110
Withdrew: Lack of efficacy27790
Withdrew: Lost to follow-up22170
Withdrew: Non-compliance with study drug410
Withdrew: Physician decision300
Withdrew: Pregnancy880
Withdrew: Withdrawal by subject41570
Withdrew: No longer met eligibility criteria (for adolescents)14290
Withdrew: No longer met eligibility criteria (for adults)420
Withdrew: Other1040
Withdrew: Approved drug available for indication0370
Main Study: Treatment Period 2
Participant flow — Main Study: Treatment Period 2
MilestoneMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine
Started2893320
Completed000
Not completed2893320
Withdrew: Adverse event220
Withdrew: Lack of efficacy700
Withdrew: Lost to follow-up210
Withdrew: Protocol violation310
Withdrew: Withdrawal by subject870
Withdrew: Other230
Withdrew: Approved drug available for indication1792220
Withdrew: Ongoing86960
Main Study Observation Period
Participant flow — Main Study Observation Period
MilestoneMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine
Started29430
Completed110
Not completed28420
Withdrew: Adverse event110
Withdrew: Lost to follow-up010
Withdrew: Pregnancy100
Withdrew: Withdrawal by subject10140
Withdrew: Other8160
Withdrew: Approved drug available for indication690
Withdrew: Ongoing210
Vaccine Sub Study
Participant flow — Vaccine Sub Study
MilestoneMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine
Started0017
Tdap vaccination with or without acwy vaccination0017
Acwy vaccination with tdap vaccination0013
Completed0016
Not completed001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryMain Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent if the event had start date on or after the first dosing date of this study.

Time frame:
From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit
ParticipantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit401515
PrimaryMain Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up Visit

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.

Time frame:
From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up Visit
ParticipantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
SAEs3042
AEs Leading to Discontinuation3646
PrimaryMain Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit

Vital signs including blood pressure included systolic blood pressure (SBP) \[Millimeters of mercury, mmHg\]) and diastolic blood pressure (DBP) and pulse rate \[beats per minute (bpm)\] were measured using an automated device in a sitting position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Criteria for vital sign abnormalities included: SBP\<90mmHg, DBP\<50 mmHg and pulse rate\<40mmHg.

Time frame:
From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
Reported as:
Count of participants · Participants
Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit
ParticipantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Diastolic blood pressure (mmHg): value <501115
Diastolic blood pressure (mmHg): change >=20 increase3970
Diastolic blood pressure (mmHg): change >=20 decrease4551
Pulse rate (bpm): Value <4013
Pulse rate (bpm): Value >12001
Systolic blood pressure (mmHg): Value <901330
Systolic blood pressure (mmHg): change>=30 increase1842
Systolic blood pressure (mmHg): change>=30 decrease2230
PrimaryMain Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up Visit

Criteria for laboratory abnormalities included:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \> 1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.

Time frame:
From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up Visit
ParticipantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Main Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up Visit390490
PrimaryVaccine Sub-study: Percentage of Participants With Tetanus Booster Response

Booster response to tetanus toxoid was defined as: \>=4-fold rise in anti-tetanus toxoid immunoglobulin G (IgG) antibody concentration at Month 1 if the pre-vaccination concentration was \<=2.7 International Units per milliliter (IU/mL); OR \>=2-fold rise in anti-tetanus toxoid IgG antibody concentration if the pre-vaccination concentration was \>2.7 IU/mL. Two-sided 95% confidence interval (CI) was based on Clopper-Pearson exact method.

Time frame:
Month 1
Reported as:
Number · Percentage of participants
Vaccine Sub-study: Percentage of Participants With Tetanus Booster Response
Percentage of participantsVaccine Sub-study: Tdap Vaccination
Vaccine Sub-study: Percentage of Participants With Tetanus Booster Response62.5 (35.4 to 84.8)
SecondaryMain Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until End of Study

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent if the event had start date on or after the first dosing date of this study.

Time frame:
From start of study intervention (Day 1) until end of study

Results for this outcome have not been posted.

SecondaryMain Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until End of Study

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.

Time frame:
From start of study intervention (Day 1) until end of study

Results for this outcome have not been posted.

SecondaryMain Study: Number of Participants With Clinically Significant Abnormalities in Vital Signs Until End of Study

Vital signs including blood pressure (systolic and diastolic blood pressure \[Millimeters of mercury, mmHg\]) and pulse rate (beats per minute \[bpm\]) were measured using an automated device in a sitting position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Clinically significant abnormalities will be determined by investigator.

Time frame:
From start of study intervention (Day 1) until end of study

Results for this outcome have not been posted.

SecondaryMain Study: Number of Participants With Clinically Significant Laboratory Abnormalities Until End of Study

Following laboratory parameters were assessed: Hemoglobin, Hematocrit, Erythrocytes Erythrocyte (ery.) corpuscular volume, Ery. Mean Corpuscular hemoglobin concentration, Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils, Monocytes, Prothrombin Time, Bilirubin, Direct Bilirubin, Indirect Bilirubin, Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase; Albumin, Urate; Urea Nitrogen, Creatinine, Cholesterol, Triglycerides, Potassium, Calcium, Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite, Leukocyte Erythrocytes, Leukocytes; Epithelial Cells, Hyaline Cast, Bacteria. Clinically significant abnormalities will be determined by investigator.

Time frame:
From start of study intervention (Day 1) until end of study

Results for this outcome have not been posted.

SecondaryMain Study: Percentage of Participants Achieving Response Based on Severity of Alopecia Tool (SALT) Overall Score <=10 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). In this outcome measure, percentage of participants with SALT overall score \<= 10 were reported. 95% CI was calculated based on normal approximation.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants Achieving Response Based on Severity of Alopecia Tool (SALT) Overall Score <=10 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Percentage of participantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 10.9 (0.02 to 1.80)27.9 (24.23 to 31.50)
Month 316.3 (12.79 to 19.83)32.6 (28.77 to 36.40)
Month 637.7 (33.07 to 42.35)39.1 (35.01 to 43.22)
Month 949.0 (44.08 to 53.91)44.7 (40.39 to 49.02)
Month 1255.8 (50.88 to 60.80)48.2 (43.72 to 52.70)
Month 1559.5 (54.50 to 64.53)52.9 (48.28 to 57.52)
Month 1862.3 (57.27 to 67.31)53.4 (48.76 to 58.12)
Month 2162.9 (57.80 to 68.00)54.9 (50.18 to 59.59)
Month 2466.4 (61.32 to 71.42)56.4 (51.69 to 61.17)
Month 2868.3 (63.23 to 73.44)59.3 (54.51 to 64.02)
Month 3269.9 (64.79 to 75.02)61.0 (56.16 to 65.76)
Month 3670.9 (65.77 to 76.12)61.7 (56.73 to 66.60)
SecondaryMain Study: Percentage of Participants Achieving Response Based on Alopecia Areata (AA) SALT Score <=10 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), with lower score indicating less hair loss. 95% CI was calculated based on normal approximation.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants Achieving Response Based on Alopecia Areata (AA) SALT Score <=10 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Percentage of participantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 11.0 (0.03 to 2.02)28.5 (24.68 to 32.35)
Month 317.7 (13.88 to 21.57)33.5 (29.52 to 37.52)
Month 639.6 (34.65 to 44.60)39.8 (35.56 to 44.05)
Month 950.7 (45.52 to 55.87)45.3 (40.90 to 49.78)
Month 1256.8 (51.56 to 61.98)49.3 (44.74 to 53.94)
Month 1561.4 (56.16 to 66.60)53.9 (49.23 to 58.64)
Month 1865.0 (59.81 to 70.09)54.1 (49.38 to 58.86)
Month 2165.2 (60.05 to 70.41)55.1 (50.37 to 59.89)
Month 2467.6 (62.47 to 72.75)57.2 (52.39 to 61.96)
Month 2869.2 (64.00 to 74.36)59.6 (54.76 to 64.35)
Month 3270.3 (65.16 to 75.50)61.6 (56.82 to 66.46)
Month 3671.1 (65.91 to 76.27)62.1 (57.17 to 67.03)
SecondaryMain Study: Percentage of Participants Achieving Response Based on SALT Overall Score <= 20 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). In this outcome measure, percentage of participants with SALT overall score \<=20 were reported. 95% CI was calculated based on normal approximation.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Reported as:
Number · Percentage of Participants
Main Study: Percentage of Participants Achieving Response Based on SALT Overall Score <= 20 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Percentage of ParticipantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 12.5 (1.05 to 3.98)35.6 (31.68 to 39.43)
Month 327.7 (23.40 to 31.92)40.2 (36.18 to 44.16)
Month 650.1 (45.33 to 54.91)50.4 (46.16 to 54.58)
Month 959.5 (54.73 to 64.37)55.9 (51.57 to 60.19)
Month 1265.5 (60.70 to 70.20)60.0 (55.59 to 64.41)
Month 1570.7 (66.00 to 75.30)62.3 (57.79 to 66.77)
Month 1871.8 (67.13 to 76.45)63.5 (59.01 to 68.05)
Month 2172.8 (68.06 to 77.45)66.3 (61.81 to 70.75)
Month 2473.5 (68.79 to 78.23)66.7 (62.16 to 71.18)
Month 2876.8 (72.17 to 81.43)69.0 (64.55 to 73.50)
Month 3278.0 (73.37 to 82.61)69.5 (64.99 to 74.05)
Month 3679.1 (74.42 to 83.69)69.7 (65.04 to 74.37)
SecondaryMain Study: Percentage of Participants Achieving Response Based on AA SALT Score <=20 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), with lower score indicating less hair loss. 95% CI was calculated based on normal approximation.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Reported as:
Number · Percentage of Participants
Main Study: Percentage of Participants Achieving Response Based on AA SALT Score <=20 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Percentage of ParticipantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 12.6 (0.99 to 4.11)36.6 (32.50 to 40.67)
Month 327.8 (23.26 to 32.29)41.2 (37.02 to 45.37)
Month 651.2 (46.13 to 56.30)51.0 (46.64 to 55.32)
Month 960.4 (55.39 to 65.50)56.5 (52.10 to 60.94)
Month 1266.0 (61.01 to 70.98)61.2 (56.75 to 65.72)
Month 1572.2 (67.35 to 76.96)63.4 (58.88 to 67.97)
Month 1874.0 (69.29 to 78.74)64.5 (59.92 to 69.02)
Month 2174.2 (69.39 to 78.91)66.6 (62.07 to 71.10)
Month 2474.8 (70.07 to 79.61)66.9 (62.36 to 71.46)
Month 2877.7 (73.03 to 82.38)69.2 (64.72 to 73.74)
Month 3278.7 (74.03 to 83.30)69.3 (64.74 to 73.88)
Month 3679.3 (74.62 to 83.89)69.9 (65.23 to 74.55)
SecondaryMain Study: Change From Baseline in SALT Overall Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing division of scalp hair into four quadrants (back, top of scalp, right side and left side), with each of four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score is sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.

Time frame:
Baseline, At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Reported as:
Mean · Units on a scale
Main Study: Change From Baseline in SALT Overall Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Units on a scaleMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 1-2.8 ± 9.94-41.8 ± 37.34
Month 3-23.6 ± 26.51-46.0 ± 37.32
Month 6-36.6 ± 32.07-52.0 ± 37.26
Month 9-44.2 ± 32.71-56.8 ± 35.89
Month 12-47.5 ± 32.34-60.1 ± 35.17
Month 15-50.6 ± 31.89-62.8 ± 33.88
Month 18-52.5 ± 31.98-64.2 ± 33.64
Month 21-53.3 ± 31.70-65.8 ± 32.43
Month 24-53.6 ± 31.79-65.5 ± 32.67
Month 28-54.8 ± 31.81-67.2 ± 32.49
Month 32-55.8 ± 31.48-67.8 ± 32.42
Month 36-56.6 ± 31.99-68.1 ± 32.17
SecondaryMain Study: Change From Baseline in AA SALT Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

SALT=quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into 4 quadrants (back, top of scalp, right side and left side), with each given an accurate determination of percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss). SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), lower score= less hair loss. Baseline (Roll-over participants: Day 1 from Study B7931005 or B7981015; De novo participants: Day 1 from Study B7981032).

Time frame:
Baseline, At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Reported as:
Mean · Units on a scale
Main Study: Change From Baseline in AA SALT Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Units on a scaleMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 1-2.9 ± 10.32-42.8 ± 37.48
Month 3-23.8 ± 26.88-47.0 ± 37.33
Month 6-37.3 ± 32.12-52.8 ± 37.05
Month 9-44.8 ± 32.73-57.4 ± 35.81
Month 12-48.5 ± 32.20-61.1 ± 34.82
Month 15-51.6 ± 31.43-63.8 ± 33.41
Month 18-53.5 ± 31.39-65.0 ± 33.16
Month 21-53.8 ± 31.57-66.0 ± 32.43
Month 24-54.1 ± 31.93-65.9 ± 32.62
Month 28-55.2 ± 32.01-67.4 ± 32.53
Month 32-56.0 ± 31.69-67.8 ± 32.55
Month 36-56.5 ± 32.04-68.2 ± 32.18
SecondaryMain Study: Percentage of Participants Achieving Atleast 75% Improvement in Overall SALT Score From Baseline at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). An Overall SALT 75 response was a 75% or greater reduction from baseline in SALT score.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants Achieving Atleast 75% Improvement in Overall SALT Score From Baseline at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Percentage of participantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 10.9 (0.02 to 1.80)37.4 (33.51 to 41.36)
Month 321.5 (17.60 to 25.43)42.6 (38.56 to 46.61)
Month 644.2 (39.40 to 48.91)51.3 (47.08 to 55.50)
Month 955.5 (50.65 to 60.41)56.9 (52.56 to 61.16)
Month 1261.8 (56.97 to 66.67)61.3 (56.88 to 65.64)
Month 1567.4 (62.60 to 72.18)64.7 (60.31 to 69.16)
Month 1868.4 (63.62 to 73.25)66.7 (62.32 to 71.17)
Month 2169.3 (64.41 to 74.14)67.9 (63.49 to 72.32)
Month 2469.9 (65.04 to 74.84)68.1 (63.64 to 72.55)
Month 2873.4 (68.50 to 78.21)70.2 (65.82 to 74.67)
Month 3276.4 (71.64 to 81.11)70.5 (66.04 to 75.01)
Month 3676.7 (71.87 to 81.51)70.8 (66.16 to 75.39)
SecondaryMain Study: Percentage of Participants Achieving Atleast 75% Improvement in AA SALT Score From Baseline at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36

SALT=quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score= SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), where lower score=less hair loss. SALT 75 response= 75% or greater reduction from baseline in AA SALT score.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants Achieving Atleast 75% Improvement in AA SALT Score From Baseline at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36
Percentage of participantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 11.0 (0.03 to 2.02)38.6 (34.52 to 42.78)
Month 322.8 (18.53 to 26.98)43.6 (39.43 to 47.84)
Month 645.6 (40.48 to 50.62)51.8 (47.43 to 56.10)
Month 957.1 (51.98 to 62.22)57.3 (52.94 to 61.76)
Month 1262.8 (57.74 to 67.91)62.3 (57.88 to 66.79)
Month 1569.2 (64.21 to 74.11)65.5 (61.03 to 69.99)
Month 1870.7 (65.79 to 75.60)67.5 (63.08 to 71.98)
Month 2170.8 (65.82 to 75.71)68.0 (63.55 to 72.48)
Month 2472.0 (67.08 to 76.95)68.4 (63.87 to 72.87)
Month 2874.8 (69.88 to 79.63)70.5 (66.02 to 74.93)
Month 3277.3 (72.60 to 82.07)70.3 (65.80 to 74.86)
Month 3677.2 (72.42 to 82.01)70.9 (66.27 to 75.51)
SecondaryMain Study: Percentage of Participants Achieving Atleast 2-Grade Improvement From Baseline or Absolute Score of 3 in the Eyebrow Assessment (EBA) at Months 1, 3, 6, 12, 18, 24 and 36 in Participants Without Normal EBA Score at Baseline

EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow. Higher scores represent lesser loss of eyebrow hair. 95% CI was based on normal approximation.

Time frame:
At Months 1, 3, 6, 12, 18, 24 and 36
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants Achieving Atleast 2-Grade Improvement From Baseline or Absolute Score of 3 in the Eyebrow Assessment (EBA) at Months 1, 3, 6, 12, 18, 24 and 36 in Participants Without Normal EBA Score at Baseline
Percentage of participantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 14.3 (2.11 to 6.53)38.8 (34.45 to 43.15)
Month 322.3 (17.69 to 26.90)43.4 (38.91 to 47.83)
Month 637.6 (32.24 to 43.00)50.0 (45.36 to 54.64)
Month 1255.0 (49.17 to 60.83)60.3 (55.44 to 65.18)
Month 1859.5 (53.55 to 65.39)64.2 (59.28 to 69.21)
Month 2461.2 (55.12 to 67.33)67.9 (62.99 to 72.87)
Month 3665.6 (59.23 to 71.93)69.9 (64.79 to 75.02)
SecondaryMain Study: Percentage of Participants Achieving Atleast 2-Grade Improvement From Baseline or Absolute Score of 3 in the Eyelash Assessment (ELA) at Months 1, 3, 6, 12, 18, 24 and 36 in Participants Without Normal ELA Score at Baseline

ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash. Higher scores represent lesser loss of eyelash hair.

Time frame:
At Months 1, 3, 6, 12, 18, 24 and 36
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants Achieving Atleast 2-Grade Improvement From Baseline or Absolute Score of 3 in the Eyelash Assessment (ELA) at Months 1, 3, 6, 12, 18, 24 and 36 in Participants Without Normal ELA Score at Baseline
Percentage of participantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 13.4 (1.34 to 5.53)37.7 (33.20 to 42.26)
Month 317.7 (13.27 to 22.19)42.5 (37.88 to 47.17)
Month 636.7 (31.03 to 42.36)47.1 (42.24 to 51.90)
Month 1254.8 (48.63 to 60.97)56.5 (51.33 to 61.66)
Month 1862.1 (55.93 to 68.33)61.2 (55.88 to 66.44)
Month 2466.2 (59.90 to 72.51)68.1 (62.89 to 73.22)
Month 3669.4 (62.73 to 75.98)70.5 (65.14 to 75.86)
SecondaryMain Study: Percentage of Participants Achieving Patient's Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Months 1, 3, 6, 9, 12, 18, 24 and 36

PGI-C is a self-administered single item questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. Participants were required to select their response on a 7-point scale ranging from 1 (greatly worsened), 2=moderately worsened, 3=slightly worsened, 4=not changed, 5= slightly improved, 6=moderately improved, 7 (greatly improved). 95% CI was based on normal approximation.

Time frame:
At Months 1, 3, 6, 9, 12, 18, 24 and 36
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants Achieving Patient's Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Months 1, 3, 6, 9, 12, 18, 24 and 36
Percentage of participantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 116.4 (12.97 to 19.91)55.2 (51.17 to 59.22)
Month 357.0 (52.34 to 61.74)59.3 (55.31 to 63.31)
Month 668.8 (64.38 to 73.21)66.4 (62.44 to 70.40)
Month 976.5 (72.34 to 80.69)69.5 (65.55 to 73.55)
Month 1278.6 (74.55 to 82.74)72.6 (68.56 to 76.59)
Month 1881.0 (76.88 to 85.03)74.8 (70.69 to 78.85)
Month 2482.4 (78.31 to 86.47)78.6 (74.65 to 82.50)
Month 3683.1 (78.77 to 87.33)79.0 (74.90 to 83.17)
SecondaryMain Study: Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Months 1, 3, 6, 9, 12, 18, 24 and 36: Emotional Symptoms and Activity Limitations

AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 5-8 assessed emotional symptoms with responses scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations with responses scored from 0='not at all' to 4='completely'. AAPPO emotional symptoms sub score was calculated as mean of items 5-8 and ranged from 0 (never) to 4 (always), where higher scores indicated more emotional symptoms. AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.

Time frame:
Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36
Reported as:
Mean · Units on a scale
Main Study: Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Months 1, 3, 6, 9, 12, 18, 24 and 36: Emotional Symptoms and Activity Limitations
Units on a scaleMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 1: Emotional Symptoms-0.33 ± 0.683-0.84 ± 1.036
Month 3: Emotional Symptoms-0.61 ± 0.867-0.86 ± 1.055
Month 6: Emotional Symptoms-0.77 ± 1.012-0.95 ± 1.087
Month 9: Emotional Symptoms-0.95 ± 1.091-0.95 ± 1.123
Month 12: Emotional Symptoms-1.00 ± 1.161-1.04 ± 1.128
Month 18: Emotional Symptoms-1.07 ± 1.174-1.11 ± 1.129
Month 24: Emotional Symptoms-1.12 ± 1.232-1.07 ± 1.172
Month 36: Emotional Symptoms-1.20 ± 1.246-1.11 ± 1.204
Month 1: Activity Limitations-0.09 ± 0.641-0.36 ± 0.789
Month 3: Activity Limitations-0.21 ± 0.667-0.38 ± 0.811
Month 6: Activity Limitations-0.27 ± 0.719-0.44 ± 0.829
Month 9: Activity Limitations-0.33 ± 0.781-0.45 ± 0.857
Month 12: Activity Limitations-0.36 ± 0.793-0.51 ± 0.871
Month 18: Activity Limitations-0.40 ± 0.830-0.51 ± 0.869
Month 24: Activity Limitations-0.43 ± 0.824-0.52 ± 0.890
Month 36: Activity Limitations-0.43 ± 0.858-0.53 ± 0.859
SecondaryMain Study: Percentage of Participants With Response Based on Hair Loss Improvement From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Months 1, 3, 6, 9, 12, 18, 24 and 36, Among Participants With Score >=2 at Baseline

AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss from the scalp, eyebrows, eyelashes and body using a 5 point scale that ranged from 0 ='no hair loss' and 4='complete hair loss'. In this outcome measure, percentage of participants with AAPPO domain scores of 0 = no hair loss or 1 = a little hair loss, among participants with score \>=2 at baseline are reported.

Time frame:
Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants With Response Based on Hair Loss Improvement From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Months 1, 3, 6, 9, 12, 18, 24 and 36, Among Participants With Score >=2 at Baseline
Percentage of participantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 1: Current hair loss on Scalp9.8 (6.96 to 12.66)37.2 (33.23 to 41.19)
Month 3: Current hair loss on Scalp27.5 (23.18 to 31.81)38.5 (34.43 to 42.49)
Month 6: Current hair loss on Scalp45.7 (40.89 to 50.55)46.4 (42.12 to 50.72)
Month 9: Current hair loss on Scalp55.6 (50.64 to 60.59)49.8 (45.37 to 54.22)
Month 12: Current hair loss on Scalp58.9 (53.91 to 63.93)52.7 (48.16 to 57.29)
Month 18: Current hair loss on Scalp62.2 (57.15 to 67.35)57.2 (52.52 to 61.97)
Month 24: Current hair loss on Scalp67.8 (62.72 to 72.86)60.7 (55.92 to 65.47)
Month 36: Current hair loss on Scalp69.3 (64.00 to 74.67)58.5 (53.34 to 63.61)
Month 1: Current hair loss on Eyebrows9.9 (6.33 to 13.38)42.9 (38.24 to 47.48)
Month 3: Current hair loss on Eyebrows32.4 (26.79 to 37.91)44.1 (39.43 to 48.79)
Month 6: Current hair loss on Eyebrows43.9 (37.94 to 49.80)49.5 (44.59 to 54.41)
Month 9: Current hair loss on Eyebrows49.0 (42.75 to 55.22)52.9 (47.88 to 57.97)
Month 12: Current hair loss on Eyebrows55.5 (49.17 to 61.85)55.0 (49.81 to 60.28)
Month 18: Current hair loss on Eyebrows60.9 (54.46 to 67.36)60.1 (54.77 to 65.48)
Month 24: Current hair loss on Eyebrows60.7 (53.94 to 67.45)64.4 (59.06 to 69.74)
Month 36: Current hair loss on Eyebrows63.8 (56.65 to 70.93)64.7 (59.08 to 70.37)
Month 1: Current hair loss on Eyelashes8.1 (4.60 to 11.57)40.9 (36.03 to 45.84)
Month 3: Current hair loss on Eyelashes35.8 (29.61 to 41.94)44.2 (39.22 to 49.20)
Month 6: Current hair loss on Eyelashes45.7 (39.21 to 52.09)46.6 (41.35 to 51.80)
Month 9: Current hair loss on Eyelashes54.2 (47.54 to 60.95)54.0 (48.57 to 59.36)
Month 12: Current hair loss on Eyelashes56.2 (49.36 to 63.08)55.3 (49.80 to 60.88)
Month 18: Current hair loss on Eyelashes61.9 (54.98 to 68.83)62.3 (56.61 to 67.94)
Month 24: Current hair loss on Eyelashes64.3 (57.15 to 71.51)65.0 (59.31 to 70.77)
Month 36: Current hair loss on Eyelashes69.8 (62.43 to 77.17)67.5 (61.55 to 73.47)
Month 1: Current hair loss on body14.7 (10.54 to 18.85)31.9 (27.51 to 36.25)
Month 3: Current hair loss on body24.3 (19.22 to 29.33)36.5 (31.96 to 41.06)
Month 6: Current hair loss on body34.6 (28.91 to 40.21)41.9 (37.06 to 46.78)
Month 9: Current hair loss on body43.7 (37.53 to 49.77)46.9 (41.82 to 51.98)
Month 12: Current hair loss on body52.3 (45.98 to 58.54)49.9 (44.60 to 55.12)
Month 18: Current hair loss on body55.9 (49.49 to 62.41)56.0 (50.52 to 61.43)
Month 24: Current hair loss on body59.1 (52.45 to 65.82)60.3 (54.75 to 65.78)
Month 36: Current hair loss on body65.2 (58.25 to 72.13)62.2 (56.44 to 68.01)
SecondaryMain Study: Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Months 1, 3, 6, 9, 12, 18, 24 and 36

HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The depression subscale comprised of 7 items with score ranging from 0 (no presence of depression) to 3 (severe feeling of depression). Total depression subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of depression symptoms. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.

Time frame:
Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36
Reported as:
Mean · Units on a scale
Main Study: Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Months 1, 3, 6, 9, 12, 18, 24 and 36
Units on a scaleMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 1-0.1 ± 2.27-0.6 ± 2.87
Month 3-0.4 ± 2.47-0.5 ± 2.80
Month 6-0.5 ± 2.60-0.7 ± 2.97
Month 9-0.6 ± 2.64-0.9 ± 2.94
Month 12-0.6 ± 2.66-0.9 ± 3.16
Month 18-0.9 ± 2.72-0.9 ± 3.08
Month 24-1.0 ± 2.75-1.1 ± 3.11
Month 36-0.8 ± 2.92-1.0 ± 2.90
SecondaryMain Study: Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Months 1, 3, 6, 9, 12, 18, 24 and 36

HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The anxiety subscale comprised of 7 items with score ranging from 0 (no anxiety) to 3 (severe anxiety). Total anxiety subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of anxiety symptoms. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.

Time frame:
Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36
Reported as:
Mean · Units on a scale
Main Study: Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Months 1, 3, 6, 9, 12, 18, 24 and 36
Units on a scaleMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 1-0.6 ± 2.57-0.9 ± 3.38
Month 3-0.7 ± 2.65-0.9 ± 3.46
Month 6-0.9 ± 2.79-1.2 ± 3.33
Month 9-0.9 ± 3.02-1.1 ± 3.46
Month 12-0.8 ± 3.14-1.1 ± 3.52
Month 18-1.0 ± 3.01-1.1 ± 3.45
Month 24-1.1 ± 3.21-1.2 ± 3.48
Month 36-1.0 ± 3.35-1.1 ± 3.46
SecondaryMain Study: Percentage of Participants With Improvement on HADS Depression Score at Months 1, 3, 6, 9, 12, 18, 24 and 36

HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The depression subscale comprised of 7 items with score ranging from 0 (no presence of depression) to 3 (severe feeling of depression). Total depression subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of depression symptoms. Improvement on HADS depression score was considered as achieving a "normal" depression subscale score indicative of an absence of depression. Among adults, a HADS-D score of 0-7 was considered "normal"; for adolescents, a HADS-D score of 0-6 was considered "normal". 95% CI was calculated based on normal approximation.

Time frame:
At Months 1, 3, 6, 9, 12, 18, 24 and 36
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants With Improvement on HADS Depression Score at Months 1, 3, 6, 9, 12, 18, 24 and 36
Percentage of participantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 153.1 (35.84 to 70.41)56.9 (44.15 to 69.64)
Month 363.3 (46.09 to 80.58)52.6 (39.67 to 65.59)
Month 670.0 (53.60 to 86.40)70.4 (58.19 to 82.55)
Month 965.5 (48.22 to 82.82)69.4 (56.48 to 82.29)
Month 1258.6 (40.70 to 76.55)72.7 (59.57 to 85.89)
Month 1884.6 (70.75 to 98.48)63.6 (49.42 to 77.85)
Month 2483.3 (68.42 to 98.24)62.8 (48.34 to 77.24)
Month 3680.0 (62.47 to 97.53)75.7 (61.85 to 89.50)
SecondaryMain Study: Percentage of Participants With Improvement on HADS Anxiety Score At Months 1, 3, 6, 9, 12, 18, 24 and 36

HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The anxiety subscale comprised of 7 items with score ranging from 0 (no anxiety) to 3 (severe anxiety). Total anxiety subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of anxiety symptoms. Improvement on HADS anxiety score was considered as achieving a "normal" anxiety subscale score indicative of an absence of anxiety. Among adults, a HADS-A score of 0-7 was considered "normal"; for adolescents, a HADS-A score of 0-8 was considered "normal". 95% CI was calculated based on normal approximation.

Time frame:
At Months 1, 3, 6, 9, 12, 18, 24 and 36
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants With Improvement on HADS Anxiety Score At Months 1, 3, 6, 9, 12, 18, 24 and 36
Percentage of participantsMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)
Month 151.1 (40.69 to 61.58)54.2 (45.25 to 63.23)
Month 346.5 (35.97 to 57.05)59.6 (50.64 to 68.65)
Month 653.6 (42.91 to 64.24)62.5 (53.53 to 71.47)
Month 950.0 (38.90 to 61.10)57.8 (48.53 to 67.07)
Month 1254.4 (43.45 to 65.41)64.4 (55.22 to 73.62)
Month 1869.9 (59.34 to 80.39)62.9 (53.27 to 72.50)
Month 2473.1 (62.52 to 83.75)61.1 (51.25 to 70.86)
Month 3662.1 (49.58 to 74.56)63.9 (53.52 to 74.19)
SecondaryVaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=1.0 International Units Per Milliliter (IU/mL) at Month 1-Tdap Vaccination

Percentage of participants with anti-tetanus antibody level \>=1.0 IU/mL at Month 1 were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.

Time frame:
Month 1
Reported as:
Number · Percentage of participants
Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=1.0 International Units Per Milliliter (IU/mL) at Month 1-Tdap Vaccination
Percentage of participantsVaccine Sub-study: Tdap Vaccination
Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=1.0 International Units Per Milliliter (IU/mL) at Month 1-Tdap Vaccination100 (79.4 to 100.0)
SecondaryVaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=0.1 IU/mL at Month 1-Tdap Vaccination

Percentage of participants with anti-tetanus antibody level \>=0.1 IU/mL at Month 1 were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.

Time frame:
Month 1
Reported as:
Number · Percentage of participants
Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=0.1 IU/mL at Month 1-Tdap Vaccination
Percentage of participantsVaccine Sub-study: Tdap Vaccination
Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=0.1 IU/mL at Month 1-Tdap Vaccination100 (79.4 to 100.0)
SecondaryVaccine Sub-study: Percentage of Participants With >=4 Times Increase in Anti-tetanus Antibody Level From Baseline at Month 1-Tdap Vaccination

Percentage of participants with \>=4 times increase in anti-tetanus antibody level from baseline were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.

Time frame:
Month 1
Reported as:
Number · Percentage of participants
Vaccine Sub-study: Percentage of Participants With >=4 Times Increase in Anti-tetanus Antibody Level From Baseline at Month 1-Tdap Vaccination
Percentage of participantsVaccine Sub-study: Tdap Vaccination
Vaccine Sub-study: Percentage of Participants With >=4 Times Increase in Anti-tetanus Antibody Level From Baseline at Month 1-Tdap Vaccination50 (24.7 to 75.3)
SecondaryVaccine Sub-study: Geometric Mean Fold Change in Anti-tetanus Levels Above Baseline Values at Month 1-Tdap Vaccination

Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Fold change was defined as the ratio of the post-baseline result to the baseline result. The assay results below the LLOQ were set to 0.5 \* LLOQ except when pre-vaccination assay results is \< LLOQ while postvaccination result is \>= LLOQ, in which case the pre-vaccination value will be set to LLOQ.

Time frame:
From Baseline (pre-vaccination on Day 1) to Month 1
Reported as:
Geometric mean · Fold change
Vaccine Sub-study: Geometric Mean Fold Change in Anti-tetanus Levels Above Baseline Values at Month 1-Tdap Vaccination
Fold changeVaccine Sub-study: Tdap Vaccination
Vaccine Sub-study: Geometric Mean Fold Change in Anti-tetanus Levels Above Baseline Values at Month 1-Tdap Vaccination5.7 (3.1 to 10.6)
SecondaryVaccine Sub-study: Geometric Mean Concentrations (GMCs) of Anti-tetanus Antibody Levels at Month 1-Tdap Vaccination

Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Assay results below the LLOQ were set to 0.5\* LLOQ.

Time frame:
Month 1
Reported as:
Geometric mean · milli-international units (mIU)/mL
Vaccine Sub-study: Geometric Mean Concentrations (GMCs) of Anti-tetanus Antibody Levels at Month 1-Tdap Vaccination
milli-international units (mIU)/mLVaccine Sub-study: Tdap Vaccination
Vaccine Sub-study: Geometric Mean Concentrations (GMCs) of Anti-tetanus Antibody Levels at Month 1-Tdap Vaccination8.4 (5.8 to 12.1)
SecondaryVaccine Sub-study: Percentage of Participants With Human Serum Bactericidal Activity (hSBA) Titer >=1:8 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination

Percentage of participants with hSBA titer \>=1.8 at 1 month post vaccination for serogroup C were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.

Time frame:
Month 1
Reported as:
Number · Percentage of Participants
Vaccine Sub-study: Percentage of Participants With Human Serum Bactericidal Activity (hSBA) Titer >=1:8 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination
Percentage of ParticipantsVaccine Sub-study: Meningococcal ACWY Vaccination
Vaccine Sub-study: Percentage of Participants With Human Serum Bactericidal Activity (hSBA) Titer >=1:8 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination20 (0.5 to 71.6)
SecondaryVaccine Sub-study: Percentage of Participants With hSBA Titer >=1:4 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination

Percentage of participants with hSBA titer \>=1.4 at 1 month post vaccination for serogroup C were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.

Time frame:
Month 1
Reported as:
Number · Percentage of Participants
Vaccine Sub-study: Percentage of Participants With hSBA Titer >=1:4 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination
Percentage of ParticipantsVaccine Sub-study: Meningococcal ACWY Vaccination
Vaccine Sub-study: Percentage of Participants With hSBA Titer >=1:4 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination40 (5.3 to 85.3)
SecondaryVaccine Sub-study: Geometric Mean Titers (GMT) of Antibodies for Serogroup C at Baseline and Month 1-Meningococcal ACWY Vaccination

Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Assay results below the LLOQ were set to 0.5\* LLOQ.

Time frame:
Baseline (pre-vaccination on Day 1) and Month 1
Reported as:
Geometric mean · Titers
Vaccine Sub-study: Geometric Mean Titers (GMT) of Antibodies for Serogroup C at Baseline and Month 1-Meningococcal ACWY Vaccination
TitersVaccine Sub-study: Meningococcal ACWY Vaccination
Baseline5.7 (3.6 to 8.8)
Month 114.1 (4.4 to 44.8)
SecondaryVaccine Sub-study: Number of Participants With SAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events.

Time frame:
From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)
Reported as:
Count of participants · Participants
Vaccine Sub-study: Number of Participants With SAEs
ParticipantsVaccine Sub-study: Tdap VaccinationVaccine Sub-study: Meningococcal ACWY Vaccination
Vaccine Sub-study: Number of Participants With SAEs00
SecondaryVaccine Sub-study: Number of Participants With AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)
Reported as:
Count of participants · Participants
Vaccine Sub-study: Number of Participants With AEs
ParticipantsVaccine Sub-study: Tdap VaccinationVaccine Sub-study: Meningococcal ACWY Vaccination
Vaccine Sub-study: Number of Participants With AEs31
SecondaryVaccine Sub-study: Number of Participants With AEs Leading to Discontinuation

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.

Time frame:
From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)
Reported as:
Count of participants · Participants
Vaccine Sub-study: Number of Participants With AEs Leading to Discontinuation
ParticipantsVaccine Sub-study: Tdap VaccinationVaccine Sub-study: Meningococcal ACWY Vaccination
Vaccine Sub-study: Number of Participants With AEs Leading to Discontinuation00

Adverse events

Collected over Main Study: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40). Vaccine Sub-study: From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)1/447 (0.2%)33/447 (7.4%)309/447 (69.1%)
Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)1/603 (0.2%)43/603 (7.1%)372/603 (61.7%)
Vaccine Sub-study: Tdap Vaccination0/17 (0%)0/17 (0%)3/17 (17.6%)
Vaccine Sub-study: Meningococcal ACWY Vaccination0/13 (0%)0/13 (0%)1/13 (7.7%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)Vaccine Sub-study: Tdap VaccinationVaccine Sub-study: Meningococcal ACWY Vaccination
Acute myocardial infarctionCardiac disorders3/4470/6030/170/13
AppendicitisInfections and infestations1/4474/6030/170/13
CholelithiasisHepatobiliary disorders0/4472/6030/170/13
Anaphylactic reactionImmune system disorders0/4472/6030/170/13
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/4472/6030/170/13
OsteoarthritisMusculoskeletal and connective tissue disorders1/4472/6030/170/13
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/4472/6030/170/13
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/4472/6030/170/13
Myocardial infarctionCardiac disorders1/4470/6030/170/13
Retinal artery occlusionEye disorders1/4470/6030/170/13
Most frequent other events
Showing 10 of 20
Most frequent other events
EventMain Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)Vaccine Sub-study: Tdap VaccinationVaccine Sub-study: Meningococcal ACWY Vaccination
SARS-CoV-2 test positiveInvestigations108/447127/6030/170/13
HeadacheNervous system disorders98/44793/6030/170/13
COVID-19Infections and infestations55/44799/6030/170/13
NasopharyngitisInfections and infestations62/44765/6030/170/13
PyrexiaGeneral disorders59/44764/6030/170/13
AcneSkin and subcutaneous tissue disorders57/44738/6030/170/13
Upper respiratory tract infectionInfections and infestations56/44773/6030/170/13
CoughRespiratory, thoracic and mediastinal disorders46/44774/6030/170/13
FatigueGeneral disorders47/44741/6030/170/13
Oropharyngeal painRespiratory, thoracic and mediastinal disorders44/44759/6030/170/13

Baseline characteristics

Full Analysis set comprised of all participants regardless of whether they received study intervention. Participants of main study and vaccine sub-study were not exclusive.

Age, Customized
Age, Customized(Participants)Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)Vaccine Sub-study: Tdap With or Without Meningococcal ACWY VaccineTotal
Main Study — From 12 to <18 Years7680—156
Main Study — From 18 to <45 Years271360—631
Main Study — From 45 to <64 Years96144—240
Main Study — >=65 Years619—25
Vaccine Substudy — From 12 to <18 Years——00
Vaccine Substudy — From 18 to <45 Years——1010
Vaccine Substudy — From 45 to <64 Years——77
Vaccine Substudy — >=65 Years——00
Sex: Female, Male
Sex: Female, Male(Participants)Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)Vaccine Sub-study: Tdap With or Without Meningococcal ACWY VaccineTotal
Main Study — Female289375—664
Main Study — Male160228—388
Vaccine Substudy — Female——1212
Vaccine Substudy — Male——55
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)Vaccine Sub-study: Tdap With or Without Meningococcal ACWY VaccineTotal
Main Study — Hispanic or Latino5576—131
Main Study — Not Hispanic or Latino383523—906
Main Study — Unknown or Not Reported114—15
Vaccine Substudy — Hispanic or Latino——44
Vaccine Substudy — Not Hispanic or Latino——1313
Vaccine Substudy — Unknown or Not Reported——00
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants)Main Study: Ritlecitinib 50 mg QD (Roll-over Participants)Vaccine Sub-study: Tdap With or Without Meningococcal ACWY VaccineTotal
Main Study — American Indian or Alaska Native53—8
Main Study — Asian96146—242
Main Study — Native Hawaiian or Other Pacific Islander21—3
Main Study — Black or African American1621—37
Main Study — White310423—733
Main Study — More than one race76—13
Main Study — Unknown or Not Reported133—16
Vaccine Substudy — American Indian or Alaska Native——00
Vaccine Substudy — Asian——33
Vaccine Substudy — Native Hawaiian or Other Pacific Islander——00
Vaccine Substudy — Black or African American——11
Vaccine Substudy — White——1313
Vaccine Substudy — More than one race——00
Vaccine Substudy — Unknown or Not Reported——00
08

Study locations

144 sites
  • The University of Alabama at Birmingham Hosptial Outreach Lab
    Birmingham, Alabama 35233, United States
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • The University of Alabama at Birmingham, Department of Dermatology
    Birmingham, Alabama 35294, United States
  • Mosaic Dermatology
    Beverly Hills, California 90211, United States
  • Univ of California, Irvine, Dermatology Clinical Research Center
    Irvine, California 92697, United States
  • Dermatology Specialists Inc.
    Murrieta, California 92562, United States
  • University of California, San Francisco
    San Francisco, California 94115, United States
  • Kaiser Permanente Clinical Trials Unit
    San Francisco, California 94118, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital Clinical and Translational Research Center
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital Outpatient Pavilion
    Aurora, Colorado 80045, United States
  • Yale School of Medicine, Yale Center for Clinical Investigations
    New Haven, Connecticut 06519, United States
  • Medstar Georgetown University Hospital - Department of Otolaryngology
    Washington D.C., District of Columbia 20007, United States
  • Medstar Georgetown University Hospital-Dept of Otolaryngology
    Washington D.C., District of Columbia 20007, United States
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • Medstar Georgetown University Hospital - Department of Pediatrics
    Washington D.C., District of Columbia 20016, United States
  • Siperstein Dermatology Group
    Boynton Beach, Florida 33472, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Velocity Clinical Research - Boise
    Meridian, Idaho 83642, United States
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
  • Northwestern Medicine Diagnostic Testing Center
    Chicago, Illinois 60611, United States
  • Northwestern Medicine
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital Investigational Drug Service Pharmacy
    Chicago, Illinois 60611, United States
  • Summit Dermatology and Aesthetic Surgery (in c/o TrialSpark, Inc)
    Oakbrook Terrace, Illinois 60181, United States
  • NorthShore University HealthSystem Dermatology Clinical Trials Unit
    Skokie, Illinois 60077, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Medstar Georgetown University Hospital - Department of Dermatology
    Chevy Chase, Maryland 20815, United States
  • Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)
    Boston, Massachusetts 02114, United States
  • University of Minnesota Clinical Research Unit (CRU)
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota Lillehei Clinical Research Unit (LCRU)
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota Medical Center, Investigational Drug Services Attn: Darlette Luke
    Minneapolis, Minnesota 55455, United States
  • Skin Specialists, PC (Schlessinger MD)
    Omaha, Nebraska 68144, United States
  • Schweiger Dermatology, P.C.
    Verona, New Jersey 07044, United States
  • NYU School of Medicine, The Ronald O. Perelman Department of Dermatology
    New York, New York 10016, United States
  • Pura Dermatology (in c/o TrialSpark, Inc)
    New York, New York 10018, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • UNC CTRC
    Chapel Hill, North Carolina 27514, United States
  • UNC Dermatology and Skin Cancer Center
    Chapel Hill, North Carolina 27516, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Vital Prospects Clinical Research Institute, P.C.
    Tulsa, Oklahoma 74136, United States
  • Oregon Medical Research Center
    Portland, Oregon 97201, United States
  • The University of Texas Health Science Center at Houston
    Bellaire, Texas 77401, United States
  • Tamjidi Skin Institute (in c/o TrialSpark, Inc)
    Vienna, Virginia 22182, United States
  • CINME Centro de Investigaciones Metabolicas
    CABA, Buenos Aires C1027AAP, Argentina
  • Psoriahue Medicina Interdisciplinaria
    CABA, C1425DKG, Argentina
  • Premier Specialists Pty Ltd
    Kogarah, New South Wales 2217, Australia
  • St George Dermatology & Skin Cancer Centre
    Kogarah, New South Wales 2217, Australia
  • The Skin Centre
    Benowa, Queensland 4217, Australia
  • Veracity Clinical Research Pty Ltd
    Woolloongabba, Queensland 4102, Australia
  • Skin Health Institute
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Eastern Canada Cutaneous Research Associates Ltd.
    Halifax, Nova Scotia B3H 1Z2, Canada
  • Sudbury Skin Clinique
    Greater Sudbury, Ontario P3C 1X8, Canada
  • Guenther Research Inc
    London, Ontario N6A 3H7, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X3, Canada
  • The Centre for Clinical Trials
    Oakville, Ontario L6J 7W5, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • York Dermatology Clinic and Research Centre
    Richmond Hill, Ontario L4C 9M7, Canada
  • Research Toronto
    Toronto, Ontario M4W 2N4, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2X 2V1, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
    Québec, Quebec G1V 4X7, Canada
  • Centro Medico Skin Med
    Santiago, LAS Condes 7580206, Chile
  • Centro Internacional de Estudios Clinicos - CIEC
    Santiago, Recoleta 8420383, Chile
  • Clinica Dermacross S.A.
    Santiago, Vitacura 7640881, Chile
  • Medical Skin Center
    Viña del Mar, 2542577, Chile
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
  • The University of Hong Kong - Shenzhen Hospital
    Shenzhen, Guangdong 518053, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, Jiangsu 210029, China
  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • Fundacion Centro de Investigacion Clinica CIC
    Medellín, Antioquia 050001, Colombia
  • Fundacion Hospitalaria San Vicente de Paul
    Medellín, Antioquia 050010, Colombia
  • Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM S.A.S
    Bogota D.C., 110221, Colombia
  • DERMAMEDICA s.r.o.
    Náchod, 547 01, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 779 00, Czechia
  • Clintrial s.r.o.
    Prague, 100 00, Czechia
  • Sanatorium profesora Arenbergera
    Prague, 110 00, Czechia
  • Fachklinik Bad Bentheim
    Bad Bentheim, 48455, Germany
  • Emovis GmbH
    Berlin, 10629, Germany
  • Universitaetsklinikum Erlangen
    Erlangen, 91054, Germany
  • University Hospital Frankfurt
    Frankfurt am Main, 60590, Germany
  • University Hospital Schleswig-Holstein
    Lübeck, 23538, Germany
  • University Hospital Muenster
    Münster, 48149, Germany
  • Nagoya City University Hospital
    Nagoya, Aichi-ken 467-8602, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Hamamatsu University Hospital
    Hamamatsu, Shizuoka 431-3192, Japan
  • Juntendo Tokyo Koto Geriatric Medical Center
    Koto-ku, Tokyo 136-0075, Japan
  • Kyorin University Hospital
    Mitaka-shi, Tokyo 181-8611, Japan
  • Osaka Metropolitan University Hospital
    Osaka, 545-8586, Japan
  • Tokyo Medical University Hospital
    Tokyo, 160-0023, Japan
  • Sociedad de Metabolismo y Corazon S.C.
    Veracruz, 91900, Mexico

Showing the first 100 of 144 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Senna M, Hanna S, Ueki R, Zhang X, Aguh C, Piraccini BM, Wajsbrot D, Nagy E, Sadrarhami M, Chen S, Wolk R, Tran H, Lejeune A. Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program. Am J Clin Dermatol. 2026 Jul 22. doi: 10.1007/s40257-026-01062-x. Online ahead of print. PubMed 42481842 ↗
  • Senna M, Soung J, Figueras I, King B, Kinoshita-Ise M, Hanna S, Wu W, Wajsbrot D, Woodworth D, Wolk R, Chaudhry A, Lejeune A, Tran H. Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies. Am J Clin Dermatol. 2026 Mar 31. doi: 10.1007/s40257-026-01029-y. Online ahead of print. PubMed 41917311 ↗
  • Ueki R, Mizuashi M, Harada K, Zhang X, Wu W, Chung WH, Kwon O, Luo X, Basey V, Wolk R, Shi N, Fujita K, Shen Y, Hirose T. Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata. J Dermatol. 2026 Apr;53(4):578-586. doi: 10.1111/1346-8138.70154. Epub 2026 Feb 6. PubMed 41645877 ↗
  • Ishowo-Adejumo R, Zareba A, Wajsbrot D, Wolk R. Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib. Dermatol Ther (Heidelb). 2026 Feb;16(2):1411-1417. doi: 10.1007/s13555-025-01648-z. Epub 2026 Jan 24. PubMed 41579233 ↗
  • King B, Mirmirani P, Lo Sicco K, Ramot Y, Sinclair R, Asfour L, Ezzedine K, Paul C, Ohyama M, Edwards RA, Bonfanti G, Kerkmann U, Wajsbrot D, Ishowo-Adejumo R, Zwillich SH, Lejeune A. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025 Jun;39(6):1163-1173. doi: 10.1111/jdv.20547. Epub 2025 Feb 17. PubMed 39962358 ↗
  • Tziotzios C, Sinclair R, Lesiak A, Mehlis S, Kinoshita-Ise M, Tsianakas A, Luo X, Law EH, Ishowo-Adejumo R, Wolk R, Sadrarhami M, Lejeune A. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. J Eur Acad Dermatol Venereol. 2025 Jun;39(6):1152-1162. doi: 10.1111/jdv.20526. Epub 2025 Jan 23. PubMed 39846397 ↗
  • Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, Magnolo N, Piraccini BM, Luo X, Wolk R, Woodworth D, Schaefer G, Lejeune A. Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025 Jan 24;192(2):215-227. doi: 10.1093/bjd/ljae365. PubMed 39432738 ↗
  • Piliang M, Lynde C, King B, Mirmirani P, Sinclair R, Senna M, Forman S, Bordone L, De La Cueva Dobao P, Wolk R, Zwillich SH, Tran H, Wajsbrot D, Ahmed HM, Takiya L. Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial. J Am Acad Dermatol. 2025 Feb;92(2):276-284. doi: 10.1016/j.jaad.2024.09.064. Epub 2024 Oct 17. PubMed 39423930 ↗
  • King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska NA, Paul C, Gong Y, Anway SD, Tran H, Wolk R, Zwillich SH, Lejeune A. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. Am J Clin Dermatol. 2024 Mar;25(2):299-314. doi: 10.1007/s40257-024-00846-3. Epub 2024 Jan 23. PubMed 38263353 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jun 2024, 59 months.

Results were first posted in Aug 2025, 1 year 1 month after primary completion.

Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2019
First posted
Jul 5, 2019
StartActual
Jul 18, 2019
Primary completionActual
Jun 25, 2024
CompletionActual
Feb 26, 2026
Results first posted
Aug 14, 2025
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04006457
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Jul 18, 2019
Primary completion
Jun 25, 2024
Completion
Feb 26, 2026
Results posted
Aug 14, 2025
Last update
Apr 9, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion